Alkermes schizophrenia drug keeps weight gain side effect in check

Alkermes Plc's schizophrenia drug met its main goal of keeping in check a common side effect of antipsychotic medicines - weight gain - taking the company one step closer to a marketing approval for the treatment.

from Reuters: Health News https://ift.tt/2AACAK5